Novartis blueprints $500M plant as pipeline fills with biologics

Novartis ($NVS) will pour half a billion dollars into building a biologics manufacturing center in Singapore as its pipeline of drugs fills up with treatments based on biologics. It joins a growing number of drugmakers and contract manufacturers that see drugs based on cell cultures as one of the best bets of the future. The company said today that work will begin early next year and is slated to be complete by 2016. Story


Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.